ALung closes $36m Series C

Artificial lung-like device developer ALung Technologies said today it closed a $36 million Series C financing round, with funds slated to support a US pivotal trial of its Hemolung respiratory assist system as it pursues FDA approval. The Pittsburgh, Penn.-based company is developing the Hemolung device, an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein. The funding round was led by Royal Philips (NYSE:PHG) and UPMC and joined by Abiomed (NSDQ:ABMD), The Accelerator Fund, Allos Ventures, Birchmere Ventures, Blue Tree Ventures and Riverfront Ventures. “Since 2013, hundreds of patients with acute respiratory failure have been successfully treated with the Hemolung RAS outside of the United States. With this new financing, we will be able to conduct our US-based clinical trial, an important step towards obtaining FDA approval and making our device available to patients in the United States. We are grateful to Philips, UPMC, and our many other investors for their commitment to ALung and the numerous patients who stand to benefit from our technology,” ALung CEO &chair Peter DeComo said in a press release. As part of the funding round, Philips patient care &monitoring systems chief medical officer Dr. Adam Seiver and UPMC’s Jeanne Cunicelli will join ALung’s board of directors, the com...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Respiratory Abiomed Inc. ALung Technologies Inc. Royal Philips Source Type: news

Related Links:

Jack Palmer, of Kansas City, Missouri, became the 20th infant under a year old to undergo a heart-lung transplant after he was born in January with a congenital heart defect.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
American Journal of Transplantation,Volume 0, Issue ja, -Not available-.
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Source Type: research
We report that the disruption of excitation-contraction coupling contributes to impaired force generation in the mouse model of Sod1 deficiency. Briefly, we found a significant reduction in sarcoplasmic reticulum Ca2+ ATPase (SERCA) activity as well as reduced expression of proteins involved in calcium release and force generation. Another potential factor involved in EC uncoupling in Sod1-/- mice is oxidative damage to proteins involved in the contractile response. In summary, this study provides strong support for the coupling between increased oxidative stress and disruption of cellular excitation contraction mac...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSIONS: Exogenous p51A gene can increase its expression in A549 and NCI-H1299 cells, suppress cell growth and induce cell apoptosis. Moreover, it can also cooperate with chemotherapy and reduce the dose and side-effect. p51A gene can suppress tumours in spite of p53 status and p21 gene might be involved. It might become a new promising therapeutic gene of tumours, which will make up for the limitation of p53 gene therapy. PMID: 30095026 [PubMed - as supplied by publisher]
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
The objective of this review is to present insights into pharmacotherapeutic techniques, which can be used for transdermal delivery of anticancer agents through skin due to its potential to create a new frontier in treatment of cancer. PMID: 30095010 [PubMed - as supplied by publisher]
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
With the development of medical technology, transplantation has prevailed and become an important tool in the treatment of disease. According to the WHO ’s statistics, as of 2015, approximately 120000 cases of solid organ transplantation have been performed globally. Renal transplantation is the most common, followed by liver transplantation, heart transplantation, lung transplantation, hematopoietic stem cell transplantation, etc. [1]. And, in re cipients of transplantation, seizures usually occur during the postoperative period [2,3].
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Tags: Review Source Type: research
This thirty-fifth adult lung and heart –lung transplant report summarizes data from 64,803 adult lung and 4,054 adult heart-lung transplants performed through June 30, 2017 and reported to the International Thoracic Organ Transplant Registry. With each year's report we now also provide more detailed analyses on a particular focus theme . Since 2013, these have been donor and recipient age; retransplantation; early graft failure; indication for transplant; and allograft ischemic time; and in 2018, multiorgan transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
AbstractPurpose of ReviewThere is a shortage of lungs available to meet the needs of patient who require lung transplantation. Ex vivo lung perfusion (EVLP) has allowed for the assessment and reconditioning of extended criteria and high-risk donor lungs, allowing for an increased volume of lung transplants. Recently, an invested interest in the utilization donation after cardiac death (DCD) donors has surfaced, in which EVLP has played an important role.Recent FindingsClinical studies have shown that EVLP can recondition donor lungs that initially would be unacceptable for transplantation. In a recent study, the interventi...
Source: Current Respiratory Care Reports - Category: Respiratory Medicine Source Type: research
Conditions:   Respiratory Failure;   Hepatitis C Intervention:   Drug: Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 12 weeks Sponsor:   Massachusetts General Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Artificial intelligence (AI) will soon become common place in radiology, and the rise of algorithm-driven technology in the medical imaging industry is poised to generate $2 billion annually by 2023, according to a report from Signify Research, a United Kingdom-based healthcare data research firm.AI has slowly been transforming the imaging market with advanced methods in assisting physicians with disease detection and diagnosis and quantification processes. At last year ’s Radiological Society of North America, the spotlightwas on AI, and various software platforms showed off their deep learning-based technologi...
Source: radRounds - Category: Radiology Authors: Source Type: blogs
More News: Clinical Trials | Funding | Hospitals | Lung Transplant | Respiratory Medicine | Science